This protocol covers patients with possible invasive pulmonary aspergillosis — a classification used when clinical and radiological findings raise suspicion but the diagnosis has not yet been confirmed as proven or probable. The distinction matters because it directly shapes which antifungal strategy is appropriate.
In possible IPA, initial empirical therapy prioritises broad antifungal coverage, including activity against Mucorales and azole-resistant Aspergillus species. Liposomal amphotericin B is the agent recommended for this scenario — selected specifically because of its wider spectrum of activity compared with the triazole class.
Complete dosing, monitoring parameters, and clinical decision criteria are available in the full structured protocol →DOI: 10.1183/16000617.0114-2022
Triazoles (voriconazole, isavuconazole or posaconazole) should be privileged for proven or probable IPA and liposomal amphotericin B for possible IPA to ensure broad coverage including the Mucorales and azole-resistant Aspergillus species.
It is also recommended as initial empirical therapy for suspected or possible invasive mould infection because of its broader spectrum of activity against pathogenic moulds including the Mucorales and azole-resistant Aspergillus species.
View source ↗